Wisepress Medical Bookshop

Therapeutic Antibodies

Methods and Protocols

Series: Methods in Molecular Biology

by Antony S. Dimitrov

Price

Quantity

€185.60
(To see other currencies, click on price)

Paperback / softback

Add to basket

€255.99
(To see other currencies, click on price)

Hardback

Add to basket

Overview

Products Details

Customer Reviews

MORE ABOUT THIS BOOK

Main description:

Over 2000 years ago in China, antibodies elicited by early forms of vaccination likely played a major role in the protection of the population from infectious agents. Vac- nation has been further developed in Europe and described by Edward Jenner in the late-eighteenth century, then successfully implemented worldwide. The idea to use theactiveingredientinthebloodofvaccinated(orimmunized)animalsorhumansfor the treatment of diseases came a century later. It was made possible by a series of discoveries,suchastherealizationthattheserumfromanimalsimmunizedwithtoxins, for example, diphtheria toxin or viruses, is an effective therapeutic against the disease causedbythesameagentinhumans. Inthe1880s,vonBehringdevelopedanantitoxin (anti-body) that did not kill the bacteria but neutralized the bacterial toxin. The first Nobel Prize in Medicine (1901) was given to him for the discovery of the serum therapy. Acenturylater,22monoclonalantibodies(mAbs)areapprovedbytheUnited States Food and Drug Administration (FDA) for clinical use, and hundreds are in clinicaltrialsforthetreatmentofvariousdiseasesincludingcancers,immunedisorders, and infections. The revenues from the top-five therapeutic antibodies reached $11. 7 billion in 2006, and major pharmaceutical companies raced to acquire antibody biotech companies with a recent example of MedImmune, Inc. , which was acquired for $15. 6 billion by AstraZeneca in 2007. This explosion of research and development in the field of therapeutic antibodies prompted the publication of the MiMB volume Therapeutic Antibodies: Methods and Protocols. The book's major goal is to present a set of protocols useful for researchers discoveringanddevelopingtherapeuticantibodies. Currentadvancesandfuturetrends in the antibody therapeutics are analyzed in the lead-in review article.

Contents:

1 Therapeutic Antibodies: Current State and Future Trends - Is a Paradigm Change Coming Soon? Dimiter S. Dimitrov and James D. Marks
PART I. Recombinant Antigens 2 Preparation of Recombinant Viral Glycoproteins for Novel and Therapeutic Antibody Discovery Yee-Peng Chan, Lianying Yan, Yan-Ru Feng, and Christopher C. Broder
PART II. Antibody Libraries
3 Design of a Human Synthetic Combinatorial Library of Single-chain Antibodies Limor Nahary and Itai Benhar 4 Construction of a Human Antibody Domain (VH) Library Weizao Chen, Zhongyu Zhu, Xiaodong Xiao, and Dimiter S. Dimitrov 5 Generation and Selection of Rabbit Antibody Libraries by Phage Display Christoph Rader 6 Construction of a Large Naive Human Phage-Displayed Fab Library through One-Step Cloning Zhongyu Zhu and Dimiter S. Dimitrov PART III. Antibody Discovery 7 Identification of Target and Function Specific Antibodies for Effective Drug Delivery Yu Zhou and James D. Marks 8 Screening of Specific Internalization Fab Fragment from Human Naive Phage Library by Combinational Bio-Panning Xin Wang and Brain B. Cao 9 Competitive Antigen Panning for Selection of HIV-1 Neutralizing Human Monoclonal Antibodies Specific for gp41 Mei-Yun Zhang and Dimiter S. Dimitrov 10 Selection of Non-Aggregating VH Binders from Synthetic VH Phage Display Libraries Mehdi Arbabi-Ghahroudi, Roger MacKenzie, and Jamshid Tanha 11 Isolation of Full-Length IgG Antibodies from Combinatorial Libraries Expressed in Escherichia Coli Yariv Mazor, Thomas Van Blarcom, Brent L. Iverson, and George Georgiou 12 Multiplexed Flow Cytometry: High-Throughput Screening of Single-ChainAntibodies Joanne Ayriss, Rosa Valero, Andrew R. M. Bradbury, and Peter Pavlik 13 Human Antibody Repertoires Per-Johan Meijer, Lars S. Nielsen, Johan Lantto, and Allan Jensen 14 Rapid Screening Platform for Stabilization of scFvs in E. coli Brian R. Miller, Scott M. Glaser, and Stephen J. Demarest
PART IV. Antibody Engineering
15 In Vitro Antibody Affinity Maturation Targeting Germline Hotspots Mitchell Ho and Ira Pastan 16 Affinity Maturation by Phage Display Holger Thie, Bernd Voedisch, Stefan Dubel, Michael Hust, and Thomas Schirrmann 17 Production of Chimeric Heavy Chain Antibodies Jianbing Zhang, Roger MacKenzie, and Yves Durocher 18 Mammalian Cell Display for Antibody Engineering Mitchell Ho and Ira Pastan 19 Improving Antibody Binding Affinity and Specificity for Therapeutic Development Jenny Bostrom, Chingwei V. Lee, Lauric Haber, and Germaine Fuh 20 Construction and Production of an IgG-like Tetravalent Bispecific Antibody for Enhanced Therapeutic Efficacy Dan Lu and Zhenping Zhu 21 Deimmunisation of Monoclonal Antibodies Frank J. Carr, Tim D. Jones, Laura J. Crompton, and Matthew P. Baker 22 Anti-CD22 Onconase: Preparation and Characterization Dianne L. Newton, Luke H. Stockwin, and Susanna M. Rybak 23 Antibody-Cytotoxic Agent Conjugates: Preparation and Characterization Rajeeva Singh and Hans K. Erickson PART V. Antibody Preclinical Development
24 High-Level Production of a Humanized ImmunoRNase Fusion Protein from Stably Transfected Myeloma Cells Jurgen Krauss, Evelyn Exner, Athanasios Mavratzas, Siegfried Seeber, and Michaela A.E. Arndt 25 Antibody Fragment Expression and Purification Dimana Dimitrova, Vidita Choudhry, and Christopher

PRODUCT DETAILS

ISBN-13: 9781627038690
Publisher: Springer (Humana Press Inc.)
Publication date: November, 2014
Pages: 585
Weight: 1275g
Availability: Available
Subcategories: Immunology, Pharmacology

Related books
Publisher recommends

Related books
From the same series

CUSTOMER REVIEWS

Average Rating